SEC Form 4 · accession 0001179110-18-003862
Tabula Rasa HealthCare, Inc. · TRHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Luehrs
Director
Period of report
Mar 6, 2018
Accepted (ET)
Mar 8, 2018 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF5,F2,F3 | Mar 6, 2018 | S | 3,115 | $36.03 | D | 230,485 | I | See footnotes |
| Common StockF1 | holding | — | — | — | 8,161 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes a restricted stock award of 3,710 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, of which shares 1,236 are vested and 2,474 are unvested. Also includes a restricted stock award of 1,855 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, all of which are vested. Also includes a restricted stock award of 2,596 shares of the Company's common stock received by Bruce Luehrs on June 16, 2017. Such common stock vests in full on the earlier of the next annual shareholder meeting or the one year anniversary of the date of grant.
- F2These securities are held by Emerald Stage2Ventures, L.P. Stage2 Capital Ventures Associates, L.P. is the general partner of Emerald Stage2 Ventures, L.P. and Stage2 Capital Associates G.P., LLC is the general partner of Stage2 Capital Ventures Associates, L.P. Bruce Luehrs, who serves as a director of the Issuer, is an officer of Stage2 Capital Associates G.P., LLC.
- F3The Reporting Person disclaims beneficial ownership (as defined in Rule 16a-1(a)(2)) of the securities reported herein (except to the extent of his pecuniary interest in such securities), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- F4The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Emerald Stage2Ventures, L.P. on January 26, 2018.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $36.00 to $36.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (5) to this Form 4.